The Effect of SSRI Exposure in Pregnancy on Early Respiratory and Metabolic Adaptation in Infants Born Preterm

Selective serotonin reuptake inhibitors (SSRIs) are increasingly used for maternal depression during pregnancy; however, their use has been linked to adverse effects in newborns. Respiratory and feeding problems, jaundice, metabolic and temperature dysregulation and hypoglycemia have been described in term infants. However, scarce data exists on early neonatal adaptation in exposed infants born prematurely. We aimed to assess the effects of SSRI exposure on early neonatal adaptation measures in infants born prematurely. Data from preterm infants exposed to maternal SSRIs during pregnancy and from matched controls were retrospectively collected. Forty-two infants comprised the final cohort: 21 infants with SSRI exposure and 21 matched controls. 1 min Apgar score was significantly lower in the exposed group compared to the non-exposed group (p = 0.043). No differences were found in 5 min Apgar scores, cord pH, need for delivery room resuscitation, rate of hypoglycemia, hyponatremia, hyperbilirubinemia, need for phototherapy, temperature stability and maximal oxygen requirements. No differences were found in the total time of respiratory support, time to reaching full enteral feeds, length of stay and complications of prematurity. Unlike studies in term infants, no significant differences were found in adaptation and short-term outcomes between preterm infants with and without SSRI exposure in pregnancy.

[1]  J. Strawn,et al.  Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications , 2022, Frontiers in Pharmacology.

[2]  Dan J Stein,et al.  Associations Between Maternal Depression, Antidepressant Use During Pregnancy, and Adverse Pregnancy Outcomes , 2021, Obstetrics and gynecology.

[3]  A. Höflich,et al.  Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta‐analysis , 2021, Acta psychiatrica Scandinavica.

[4]  F. Uguz.  The Relationship Between Maternal Antidepressants and Neonatal Hypoglycemia: A Systematic Review , 2021, Alpha psychiatry.

[5]  E. Miller,et al.  Acute Delivery Room Resuscitation of SSRI Exposed Neonates. , 2021, The Journal of pediatrics.

[6]  G. Corrao,et al.  Use of antidepressants during pregnancy and neonatal outcomes: An umbrella review of meta-analyses of observational studies. , 2020, Journal of psychiatric research.

[7]  C. Eap,et al.  Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update , 2019, Expert opinion on drug safety.

[8]  E. Clementi,et al.  Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure , 2019, Front. Pediatr..

[9]  S. Reif,et al.  Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta‐analysis, and network meta‐analysis , 2019, American journal of obstetrics and gynecology.

[10]  T. Oberlander,et al.  Variations in Neurodevelopmental Outcomes in Children with Prenatal SSRI Antidepressant Exposure , 2017, Birth defects research.

[11]  L. Rasmussen-Torvik,et al.  Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates. , 2017, The Journal of clinical psychiatry.

[12]  Steven P. Miller,et al.  Antenatal exposure to antidepressants is associated with altered brain development in very preterm-born neonates , 2017, Neuroscience.

[13]  A. Bérard,et al.  Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort , 2017, BMJ Open.

[14]  A. Hogue,et al.  Effects of in-utero exposure to selective serotonin reuptake inhibitors and venlafaxine on term and preterm infants. , 2017, Journal of neonatal-perinatal medicine.

[15]  G. Saccone,et al.  Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta‐analysis , 2016, BJOG : an international journal of obstetrics and gynaecology.

[16]  S. M. Herod,et al.  Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy , 2016, ACS chemical neuroscience.

[17]  A. Robb,et al.  SSRI use during pregnancy. , 2015, Seminars in perinatology.

[18]  S. Hernández-Díaz,et al.  Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. , 2015, JAMA.

[19]  L. Forsberg,et al.  Neonatal Adaptation in Infants Prenatally Exposed to Antidepressants- Clinical Monitoring Using Neonatal Abstinence Score , 2014, PloS one.

[20]  B. Mintzes,et al.  Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance , 2014, BMC Pregnancy and Childbirth.

[21]  Mary K. Kowal,et al.  Antidepressant use in pregnancy and the risk of cardiac defects. , 2014, The New England journal of medicine.

[22]  C. Dennis,et al.  Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis , 2014, BMJ : British Medical Journal.

[23]  J. Kuint,et al.  Short-Term Neonatal Outcome among Term Infants after in utero Exposure to Serotonin Reuptake Inhibitors , 2013, Neonatology.

[24]  G. Aylward,et al.  In Utero Antidepressant Exposure and Neurodevelopment in Preterm Infants , 2012, American Journal of Perinatology.

[25]  L. Lazzeroni,et al.  Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development , 2011, Psychopharmacology.

[26]  G. Diamond,et al.  Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome , 2011, Journal of Perinatology.

[27]  Satish Iyengar,et al.  A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. , 2010, Archives of general psychiatry.

[28]  Lisa M Bodnar,et al.  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. , 2009, The American journal of psychiatry.

[29]  A. Carceller,et al.  Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates , 2007, Pediatrics.

[30]  C. Hertzman,et al.  Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. , 2006, Archives of general psychiatry.

[31]  L. Sirota,et al.  Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. , 2006, Archives of pediatrics & adolescent medicine.

[32]  L. Altshuler,et al.  Placental passage of antidepressant medications. , 2003, The American journal of psychiatry.

[33]  R. Grunau,et al.  Prolonged Prenatal Psychotropic Medication Exposure Alters Neonatal Acute Pain Response , 2002, Pediatric Research.

[34]  E. Bancalari,et al.  Bronchopulmonary dysplasia. , 2001, American journal of respiratory and critical care medicine.

[35]  L. Papile,et al.  Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. , 1978, The Journal of pediatrics.

[36]  M. J. Bell,et al.  Neonatal Necrotizing Enterocolitis: Therapeutic Decisions Based upon Clinical Staging , 1978, Annals of surgery.

[37]  R. Yohe.  Respiratory distress in the newborn. , 1958, Journal. Iowa State Medical Society.